Internal Medicine, Cardiovascular Disease · Miami Beach, FL
NPI
1720037690
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
4302 Alton Rd, 1003
Miami Beach, FL, 33140
Phone (305) 672-0290
Groups this clinician bills Medicare through
Medicare paid, 2024
$572K
6,582 services
Medicare patients, 2024
979
Average age 78
Drug cost, 2024
$1.8M
11,388 prescriptions
Company payments, 2025
$483
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pablo H Vivas was code 93000 (electrocardiogram), 1,627 times for 801 patients. In total Pablo H Vivas billed 6,582 services in 49 codes, and Medicare paid $572K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-03-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 93000 Electrocardiogram | Office | 1,627 | 801 | $10.45 | $17K |
| 99214 Office E&M - Established | Office | 1,476 | 714 | $92.08 | $136K |
| 93306 Echocardiography (TTE/TEE) | Office | 577 | 571 | $151.84 | $88K |
| 99231 Hospital E&M - Subsequent | Facility | 356 | 107 | $41.89 | $15K |
| 99232 Hospital E&M - Subsequent | Facility | 303 | 150 | $65.26 | $20K |
| A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 290 | 145 | $351.48 | $102K |
| 99213 Office E&M - Established | Office | 244 | 189 | $71.23 | $17K |
| 36415 Venipuncture Blood Collection | Office | 216 | 152 | $8.61 | $1,860 |
| 99233 Hospital E&M - Subsequent | Facility | 197 | 128 | $97.40 | $19K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 172 | 43 | $5.90 | $1,015 |
| 93015 Electrocardiogram | Office | 162 | 162 | $50.40 | $8,164 |
| 78452 Myocardial Perfusion Scan | Office | 160 | 160 | $345.49 | $55K |
| 99204 Office E&M - New | Office | 137 | 137 | $126.75 | $17K |
| 99221 Hospital E&M - Initial | Facility | 114 | 92 | $68.99 | $7,865 |
| 99222 Hospital E&M - Initial | Facility | 88 | 82 | $109.40 | $9,627 |
By year: 2022 $590K for 7,174 services; 2023 $616K for 6,814 services; 2024 $572K for 6,582 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 216 | 152 | $8.61 | $1,860 |
Medicare prescription drug claims, 2024
In 2024, the drug Pablo H Vivas prescribed most often to Medicare patients was Losartan Potassium, with 1,143 prescriptions and refills. In total Pablo H Vivas wrote 11,388 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Losartan Potassium Generic | 1,143 | 3,336 | 382 | $9,844 |
| Metoprolol Succinate Generic | 1,013 | 2,910 | 336 | $11K |
| Amlodipine Besylate Generic | 759 | 2,227 | 264 | $4,707 |
| Eliquis Apixaban | 650 | 1,396 | 188 | $808K |
| Atorvastatin Calcium Generic | 619 | 1,795 | 213 | $5,697 |
| Clopidogrel Clopidogrel Bisulfate | 389 | 1,130 | 133 | $4,049 |
| Labetalol Hcl Generic | 382 | 1,002 | 108 | $10K |
| Lisinopril Generic | 371 | 1,096 | 127 | $2,466 |
| Nebivolol Hcl Generic | 313 | 832 | 103 | $31K |
| Rosuvastatin Calcium Generic | 281 | 813 | 104 | $5,121 |
| Amiodarone Hcl Generic | 247 | 665 | 82 | $5,054 |
| Entresto Sacubitril/Valsartan | 231 | 479 | 61 | $317K |
| Metoprolol Tartrate Generic | 216 | 605 | 70 | $1,539 |
| Doxazosin Mesylate Generic | 194 | 532 | 58 | $2,776 |
| Hydrochlorothiazide Generic | 193 | 573 | 74 | $1,448 |
Brand drugs: - claims; generic drugs: 9,746 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pablo H Vivas $483 ($483 in general payments such as food, travel and fees) from 4 companies. The largest payer was Novartis Pharmaceuticals Corporation with $281.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.